Table 2. Effects of CUMS and escitalopram treatment on hippocampal 1H-MRS measurements.
| Laterality | Metabolites | CON+saline | CON+ESC | CUMS+saline | CUMS+ESC |
| Left | NAA/Cr | 1.18±0.09 | 1.22±0.08 | 1.14±0.06 | 1.13±0.03 |
| Cho/Cr | 0.16±0.02 | 0.18±0.02 | 0.19±0.02 | 0.18±0.03 | |
| Glu/Cr | 1.17±0.14 | 1.18±0.26 | 1.09±0.18 | 0.94±0.16 | |
| MI/Cr | 0.68±0.04 | 0.80±0.21 | 0.67±0.10 | 0.67±0.04 | |
| Right | NAA/Cr | 1.35±0.09 | 1.22±0.15 | 1.11±0.05** | 1.29±0.10# |
| Cho/Cr | 0.20±0.02 | 0.21±0.04 | 0.19±0.02 | 0.18±0.01 | |
| Glu/Cr | 1.29±0.09 | 1.16±0.22 | 1.14±0.12 | 1.09±0.10 | |
| MI/Cr | 0.68±0.08 | 0.65±0.11 | 0.62±0.05 | 0.69±0.09 |
Data are presented as mean ± S.D. (n = 6 per group).
**P<0.005 vs. control+saline group,
#
P<0.05 vs. CUMS+saline group. Abbreviations: CON, control; CUMS, chronic unpredictable mild stress; ESC, escitalopram; NAA, N-acetylaspartate; Cr, creatine; Cho, choline-containing compounds; Glu, glutamate; MI, Myo-inositol.